Sagittarius Life Science Corp
Sagittarius Life Science Corp is a food processing company operating in the Consumer Non-Cyclicals sector, specializing in the production and distribution of food products.
Business. Sagittarius Life Science Corp (3205.TWO) is a food processing company operating within the Consumer Non-Cyclicals sector. The firm is listed on the Taiwan Premium Exchange (TPEx). Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Sagittarius Life Science Corp (3205.TWO) is a food processing company operating within the Consumer Non-Cyclicals sector. The firm is listed on the Taiwan Premium Exchange (TPEx). Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
Sagittarius Life Science Corp maintains a strong liquidity position, with a current ratio of 2.92, indicating that it has nearly three times more current assets than current liabilities. The company holds TWD 140.21 million in cash and equivalents, which is a significant portion of its total assets of TWD 619.54 million. However, the company's liquidity is not supported by positive operating cash flow, as it reported negative operating cash flow of TWD -18.10 million in the latest period.
Profitability metrics show a challenging performance, with a return on equity (ROE) of -1.89% and a return on assets (ROA) of -1.51%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating loss of TWD -15.45 million and net loss of TWD -9.35 million further underscore the company's financial difficulties.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases the company's exposure to market-specific risks and limits its ability to offset losses in one area with gains in another.
Growth prospects appear limited in the near term, as the company has not provided forward-looking guidance or outlook for the current or next fiscal year. The absence of capital expenditures and the negative free cash flow of TWD -7.22 million suggest that the company is not investing in expansion or innovation.
Risk factors include the company's negative operating and net income, which could lead to increased financial pressure and potential liquidity constraints in the future. The company has not issued any recent equity, and there are no immediate dilution risks based on the latest filings.
No recent events, such as earnings calls, regulatory filings, or press releases, have been disclosed that would indicate a material change in the company's operations or strategy.
- Sagittarius Life Science Corp has a strong liquidity position but is not generating positive operating cash flow.
- The company is unprofitable, with negative returns on equity and assets.
- Revenue and operations are not diversified across segments or geographies.
- There is no indication of near-term growth or capital investment.
- The company does not currently face immediate liquidity or dilution risks.
Bull / Bear case
Generated · model-assistedThe company maintains a low debt-to-equity ratio of 0.03, significantly below the Food Processing cohort median of 0.32.
Cash conversion efficiency stands at 1.94, outperforming the Food Processing cohort median of 0.98.
Dilution and liquidity risks are assessed as low, suggesting stable capital structure and marketability.
Gross profit reached TWD 57.7 million in the latest period, indicating positive contribution margins despite operating losses.
Long-term debt decreased to TWD 385,000 in the latest period, reflecting reduced leverage obligations.
The company faces high credit risk, indicating potential difficulties in meeting financial obligations or securing financing.
Free cash flow remained negative at TWD -40.1 million, indicating ongoing cash burn despite revenue generation.
In focus — financials by report
Revenue TWD 529.1M, −10,0% YoY; Operating income +8,7% YoY.
- ▍Revenue TWD 529.1M, −10,0% YoY
- ▍Operating income +8,7% YoY
- ▍Net income +14,1% YoY
- ▍Free cash flow +20,1% YoY
- ▍Net margin -14.0%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Sagittarius Life Science Corp Market data — financials · 2026-05-26